WO2023282796A3 - Pharmaceutical composition of non-enveloped virus - Google Patents

Pharmaceutical composition of non-enveloped virus Download PDF

Info

Publication number
WO2023282796A3
WO2023282796A3 PCT/RU2022/050212 RU2022050212W WO2023282796A3 WO 2023282796 A3 WO2023282796 A3 WO 2023282796A3 RU 2022050212 W RU2022050212 W RU 2022050212W WO 2023282796 A3 WO2023282796 A3 WO 2023282796A3
Authority
WO
WIPO (PCT)
Prior art keywords
enveloped virus
pharmaceutical composition
compositions
virus
recombinant
Prior art date
Application number
PCT/RU2022/050212
Other languages
French (fr)
Other versions
WO2023282796A2 (en
Inventor
Lina Igorevna FEDORENKO
Ekaterina Aleksandrovna LOMKOVA
Aleksandr Olegovich IAKOVLEV
Aleksandra Aleksandrovna SOZONOVA
Marina Konstantinovna DVORIANKINA
Dmitry Valentinovich MOROZOV
Original Assignee
Joint Stock Company «Biocad»
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021120143A external-priority patent/RU2021120143A/en
Application filed by Joint Stock Company «Biocad» filed Critical Joint Stock Company «Biocad»
Priority to CN202280061040.XA priority Critical patent/CN117999353A/en
Priority to EP22838112.5A priority patent/EP4367252A2/en
Publication of WO2023282796A2 publication Critical patent/WO2023282796A2/en
Publication of WO2023282796A3 publication Critical patent/WO2023282796A3/en
Priority to CONC2024/0000073A priority patent/CO2024000073A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to the field of pharmaceuticals, gene therapy and medicine, specifically to pharmaceutical compositions of a vector based on recombinant non-enveloped virus, in particular the recombinant adeno-associated virus (rAAV), which compositions may be aqueous or lyophilized compositions and may be used for the treatment and prevention of various diseases.
PCT/RU2022/050212 2021-07-08 2022-07-04 Pharmaceutical composition of non-enveloped virus WO2023282796A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202280061040.XA CN117999353A (en) 2021-07-08 2022-07-04 Pharmaceutical composition of non-enveloped virus
EP22838112.5A EP4367252A2 (en) 2021-07-08 2022-07-04 Pharmaceutical composition of non-enveloped virus
CONC2024/0000073A CO2024000073A2 (en) 2021-07-08 2024-01-05 Pharmaceutical composition of non-enveloped virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021120143A RU2021120143A (en) 2021-07-08 PHARMACEUTICAL COMPOSITION OF NON-ENCOUNTERED VIRUS
RU2021120143 2021-07-08

Publications (2)

Publication Number Publication Date
WO2023282796A2 WO2023282796A2 (en) 2023-01-12
WO2023282796A3 true WO2023282796A3 (en) 2023-02-16

Family

ID=84800844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2022/050212 WO2023282796A2 (en) 2021-07-08 2022-07-04 Pharmaceutical composition of non-enveloped virus

Country Status (6)

Country Link
EP (1) EP4367252A2 (en)
CN (1) CN117999353A (en)
AR (1) AR126417A1 (en)
CO (1) CO2024000073A2 (en)
EC (1) ECSP24001599A (en)
WO (1) WO2023282796A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116280A2 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
WO2015040002A1 (en) * 2013-09-19 2015-03-26 Crucell Holland B.V. Improved adenovirus formulations
WO2018128689A1 (en) * 2016-11-04 2018-07-12 Baxalta Incorporated Adeno-associated virus formulations
WO2020023612A1 (en) * 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116280A2 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
WO2015040002A1 (en) * 2013-09-19 2015-03-26 Crucell Holland B.V. Improved adenovirus formulations
WO2018128689A1 (en) * 2016-11-04 2018-07-12 Baxalta Incorporated Adeno-associated virus formulations
WO2020023612A1 (en) * 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAEUSER CHRISTINA, GOLDBACH PIERRE, HUWYLER JOERG, FRIESS WOLFGANG, ALLMENDINGER ANDREA: "Excipients for Room Temperature Stable Freeze-Dried Monoclonal Antibody Formulations", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN CHEMICAL SOCIETY AND AMERICAN PHARMACEUTICAL ASSOCIATION, US, vol. 109, no. 1, 1 January 2020 (2020-01-01), US , pages 807 - 817, XP093035734, ISSN: 0022-3549, DOI: 10.1016/j.xphs.2019.10.016 *

Also Published As

Publication number Publication date
CN117999353A (en) 2024-05-07
AR126417A1 (en) 2023-10-11
EP4367252A2 (en) 2024-05-15
ECSP24001599A (en) 2024-02-29
CO2024000073A2 (en) 2024-04-29
WO2023282796A2 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
WO2019028306A3 (en) Compositions and methods for delivery of aav
EP4219695A3 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
WO2017197355A3 (en) Adeno-associated virus variant capsids and methods of use thereof
EP4218828A3 (en) Adeno-associated virus variant capsids and methods of use thereof
Weng et al. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells
WO2019222444A3 (en) Directed evolution of aav to improve tropism for cns
WO2020028751A3 (en) Aav variants with enhanced tropism
WO2001016330A3 (en) Prevention of affections associated with porcine circovirus-2
BR0211742A (en) Active Aminoisoxazole Derivatives as Kinase Inhibitors
ZA202211060B (en) Anti-viral compounds and methods for administration thereof
GB201018518D0 (en) Novel endolysin
WO2020219766A8 (en) Compositions useful in treatment of rett syndrome
BRPI0510016B8 (en) recombinant lentiviral vector, immunogenic composition and their use as a vaccine
BR112021015751A2 (en) Gene therapy vectors for the treatment of danon's disease
MD20190018A2 (en) Composition, in particular a preventive and curative pharmaceutical composition, made from peroxometallate
BR112022004058A2 (en) Conjugates, populations of conjugates, pharmaceutical composition, methods for treating a subject with a viral infection, the prophylactic treatment of a viral infection, for preventing a secondary infection and for treating or preventing a viral infection
MX2021010356A (en) Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy.
WO2023282796A3 (en) Pharmaceutical composition of non-enveloped virus
BR112022019729A2 (en) INVERTED TERMINAL REPEAT (ITR), NUCLEIC ACID VECTOR, RECOMBINANT ADENO-ASSOCIATED VIRUS PARTICLE, PHARMACEUTICAL COMPOSITION AND METHODS OF DELIVERY OF A NUCLEIC ACID AND OF PREVENTION OR TREATMENT OF A DISEASE
GB2546439A (en) Ezrin-derived peptides and pharmaceutical compositions thereof
WO2021025995A9 (en) Aav variants with enhanced tropism
MX2022002766A (en) Influenza virus vaccines and uses thereof.
WO2021233766A8 (en) Compounds binding tenascin-c (tnc) for use in the treatment of diseases
WO2022129097A3 (en) Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
WO2021226267A3 (en) Cross-species compatible adeno-associated virus compositions and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22838112

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2401000059

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 000042-2024

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2024/000472

Country of ref document: MX

Ref document number: P6000053/2024

Country of ref document: AE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024000158

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202490189

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2022838112

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 112024000158

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240104